Google
Trusted Resources: People & Places
Healthcare providers, researchers, and advocates
David Beidler, PhD
Researcher Senior Director, Precision Medicine, Early Clinical Development
Pfizer Inc.
Global Research and Development -
Rare Diseases Research Unit
1 Portland Street
Cambridge, Massachusetts, United States
As the Translational Sciences lead for the phosphodiesterase type 9 inhibitor project, Dr. Beidler contributed to the development, implementation, and analysis of pharmacodynamic biomarkers in the recent phase 1b study in stable sickle cell disease subjects. Dr. Beidler has over 17 years of pharmaceutical industry experience with biomarker/translational pharmacology strategy and clinical operations that span preclinical animal models, natural history/methodology studies, and early (Phase 1/2) clinical trials. Dr. Beidler has also served as the research project team leader and in vivo pharmacology lead on several pain/inflammation project teams that delivered multiple candidate compounds to the clinic.
Representative Publications:
Safety and Tolerability of PF-04447943 across a Clinical Trial Program Including 277 Patients
+myBinderRelated Content
-
Sickle Cell Disease Program at Children’s HealthThe Sickle Cell Disease Program at Child...
-
Laura De Castro, MDLaura M. De Castro MD, MHSc, is an Assoc...
-
Sandeep Soni, MDSandeep Soni, MD, is the Executive Direc...
-
A Developmental Examination of Pain Among Youth with Sickle Cell DiseaseIntroduction: Sickle cell disease (SCD)...
-
Nationwide Children’s HospitalThe Comprehensive Sickle Cell and Thalas...
-
3 Tips about Sickle Cell Disease – Every emergency provider needs to knowChildren and adults with sickle cell dis...
-
Annual Sickle Cell Disease and Thalassaemia Conference (ASCAT) 2022The Annual Scientific Conference on Sick...
